Southern Co (SO) Stock News

Zacks presents its Focus List, a curated portfolio of 50 stocks selected based on positive earnings estimate revisions. The list has historically outperformed the S&P 500, with cumulative returns of 2,519.23% since February 1996 compared to the S&P's 854.95%. The methodology relies on the Zacks Rank system, which evaluates stocks based on earnings consensus among analysts. Solventum (SOLV), a healthcare company spun off from 3M, is highlighted as a recent addition that has gained 29.89% since April 2024.

While major market indices declined on September 14, 2026, SoFi Technologies (SOFI) gained 1.91% to close at $17.65. The stock outperformed the broader market despite the S&P 500 falling 0.48%. Analysts expect strong earnings growth with EPS projected at $0.17 (up 54.55% YoY) and revenue of $1.24 billion (up 31.08% YoY). However, SOFI trades at a premium valuation with a Forward P/E of 28.73 versus its industry average of 11.74, and currently holds a Zacks Rank of #3 (Hold).

SoundHound AI (SOUN) has an average brokerage recommendation of 1.75 (Strong Buy/Buy) with five of eight firms rating it Strong Buy. However, the article cautions that brokerage recommendations often have positive bias due to vested interests. The company's Zacks Rank #2 (Buy) rating is based on a 21.8% increase in consensus earnings estimates over the past month, suggesting analyst optimism about near-term price appreciation.

Bristol Myers Squibb's SOTYKTU (deucravacitinib), a first-in-class TYK2 inhibitor, has received FDA approval for psoriatic arthritis in March 2026, expanding its commercial potential beyond plaque psoriasis. The drug demonstrates sustained efficacy with PASI 75 response rates of 67%-73% through five years and over 5,000 patient-years of safety data. Market analysis forecasts SOTYKTU sales across seven major markets through 2034, with growth driven by oral convenience, selective mechanism of action, and potential expansion into additional immune-mediated inflammatory disease indications including lupus, Sjogren's syndrome, and Crohn's disease.

Comstock Resources (CRK) has announced a $1.65 billion strategic partnership with Azerbaijan's SOCAR and a $450 million drilling joint venture with Jerry Jones. The deals will reduce pro forma net debt from $3.1 billion to $1.5 billion, provide LNG marketing capabilities, and fund drilling of 27 wells in the Haynesville while CRK retains operational control. The SOCAR transaction is expected to close by year-end 2026.

Revolution Medicines announced publication of Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) in previously treated RAS mutant non-small cell lung cancer in the New England Journal of Medicine. The trial showed a 42% objective response rate and 16.0 months median overall survival in a docetaxel-naïve subgroup, with a manageable safety profile. Results support the ongoing Phase 3 RASolve 301 trial.

Solventum Corporation (SOLV), a healthcare company spun off from 3M, has been added to the Zacks Focus List. The stock has gained 31.53% since its April 2024 IPO at $69.15, now trading at $90.95. Six analysts raised earnings estimates in the last 60 days, with consensus estimates increasing $0.55 to $7.13 for fiscal 2026. The company is expected to deliver 16.7% earnings growth for the current fiscal year and has demonstrated a 13.2% average earnings surprise.

The iShares Semiconductor ETF (SOXX) receives a Zacks ETF Rank of 1 (Strong Buy) due to its low expense ratio of 0.33%, strong year-to-date performance of 66.3%, and broad exposure to the semiconductor sector. However, the ETF carries high risk with a beta of 1.80 and standard deviation of 38.8%, with concentrated exposure through top holdings like Nvidia (8.77%), Micron Technology, and Advanced Micro Devices.

YieldMax® announced monthly distributions for three Target 12™ ETFs on September 1, 2026. BIGY, RNTY, and SOXY each maintain a 12% target annual income level with distributions per share of $0.5265, $0.4879, and $0.8828 respectively. The announcement includes risk disclosures noting that distributions are variable and may be zero, with no guarantee of future performance.

Disc Medicine announced it will present clinical data from multiple programs at the SOHO 2026 Annual Meeting in Houston, including initial Phase 2 RESTORE-PV trial data for DISC-3405 in polycythemia vera patients and efficacy data from the RALLY-MF trial of DISC-0974 for myelofibrosis-associated anemia. The oral presentations are scheduled for September 9-12, 2026.

SoFi Technologies is transitioning from an online lender to a broad digital financial-services platform, with 51% of new products opened by existing members in Q2 (up from 35% YoY). The company's adjusted net revenues rose 40% YoY and adjusted EBITDA increased 44%, driven by cross-buy adoption and non-lending offerings now accounting for 87% of total products. However, SOFI stock has declined in 2026 despite operational progress, and current valuation assumes continued execution on its ecosystem strategy.

While Wall Street analysts show strong bullish sentiment on MINISO Group Holding Limited with an average brokerage recommendation of 1.50 (Strong Buy), the article cautions investors to rely more on Zacks Rank analysis. MINISO received a Zacks Rank #3 (Hold) rating due to unchanged earnings estimates of $1.56 for the current year, suggesting the stock may perform in line with the broader market rather than outperform.

HUTCHMED announced positive Phase III SANOVO trial results showing that ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) demonstrated statistically significant progression-free survival improvements and encouraging overall survival benefits in treatment-naïve patients with MET-overexpressing EGFR-mutated NSCLC in China, extending the clinical value of the combination into the first-line setting.

BNP Paribas has issued a statement regarding ongoing Sudan litigation, asserting that the trial court misinterpreted Swiss law and committed legal errors. The bank claims its financial transactions were authorized under Swiss and European law, and states it has support from the Swiss and US governments, academics, and professional organizations. BNP Paribas expressed confidence in presenting its case before the appellate court.

Onco360, the nation's leading independent specialty pharmacy, has been selected as a pharmacy partner by Revolution Medicines for the launch of RASONQUE (daraxonrasib), a RAS GTPase inhibitor for metastatic pancreatic adenocarcinoma. The drug showed significant clinical benefits in the phase 3 RASolute-302 trial, with median PFS of 7.3 months and OS of 13.2 months in RAS G12 mutation patients compared to 3.5 months and 6.6 months respectively for chemotherapy.

The FDA has approved RASONQUE (daraxonrasib), developed by Revolution Medicines, as the first targeted RAS inhibitor for treating metastatic pancreatic adenocarcinoma in patients who have received prior systemic therapy or are not candidates for multiagent chemotherapy. In the Phase 3 RASolute 302 trial, RASONQUE reduced the risk of death by 60% compared to chemotherapy, with median overall survival of 13.2 months versus 6.7 months, and demonstrated manageable safety with improved quality of life measures.

SOXX semiconductor ETF is outperforming SMH by 16.54 percentage points YTD due to its more balanced portfolio structure. While SMH concentrates over 30% in its top two holdings, SOXX keeps no single stock above 9%, reducing risk and positioning it better to benefit from broad chip industry growth while limiting downside if major players stumble.

Law firm Bragar Eagel & Squire is investigating First Solar for potential breach of fiduciary duties, alleging the company made false statements about its capacity to manage U.S. tariff impacts and understated negative effects from production facility underutilization in Malaysia and Vietnam, as well as U.S. relocation efforts on 2026 fiscal year performance.

Solana's price has dropped over 70% from its all-time high of $293.31 to $77, but analyst Leo Sun believes three catalysts could drive it back above $200 within two years: macro environment stabilization with Fed rate cuts, growing adoption of stablecoins and tokenized real-world assets, and passage of the CLARITY Act for digital asset regulation. Solana's superior transaction speed compared to Ethereum and partnerships with major financial institutions like BlackRock, Visa, and Shopify support its potential recovery.

The iShares Semiconductor ETF (SOXX) and Fidelity MSCI Information Technology Index ETF (FTEC) offer different approaches to tech investing. SOXX focuses exclusively on semiconductors with 30 concentrated holdings and higher volatility but stronger 1-year returns (119%), while FTEC provides broader tech diversification across nearly 300 stocks with lower fees and reduced risk. The choice depends on investor risk tolerance and portfolio goals.

The iShares Semiconductor ETF (SOXX) dropped 21.2% in July after rallying 112.8% in the first half of 2026. The decline was driven by multiple factors: short-seller Michael Burry's bearish stance on overvalued AI stocks, the release of China's capable low-cost Kimi K3 AI model raising competition concerns, and forced liquidation of the leveraged AI hedge fund Situational Awareness. Despite the pullback, strong semiconductor earnings showed no weakness in AI chip demand.

Law firm Julie & Holleman is investigating Personalis' proposed acquisition by Tempus AI for $16.25 per share, raising concerns about fair value and potential conflicts of interest given Tempus' existing significant equity stake and strategic partnership with Personalis since 2023.

Ferrari N.V. announced Q2 2026 net revenues of €1,938 million (up 8% YoY), operating profit of €605 million with a 31.2% margin, and net profit of €463 million. The company raised its 2026 guidance citing stronger-than-expected personalizations and lower currency headwinds. The order book covers deliveries through 2027, with new model launches including the Ferrari Luce and 12Cilindri Manuale contributing to the company's most complete product lineup in history.

SOUND Behavioral Health, celebrating 60 years of service in the Puget Sound region, has launched a Corporate Community Partner Program to expand behavioral healthcare access across King County. Five founding partners—BNBuilders, Columbia Bank, JTM Construction, West Monroe, and Manson Construction—will support the initiative through financial contributions, volunteerism, and employee engagement while advancing their corporate social responsibility goals.

SOLOWIN HOLDINGS (Nasdaq: AXG) announced a strategic partnership with ATTRUS to develop financial services in Latin America, focusing on cross-border payments, stablecoin on/off-ramp services, and digital financial infrastructure in Mexico and Brazil. The collaboration combines AXG's blockchain technology and AI-driven payment routing with ATTRUS's local financial networks. Additionally, AX Coin, a subsidiary of AXG, received the first stablecoin issuer license from the Central Bank of Bahrain and partnered with Bank of Bahrain and Kuwait for regulated stablecoin infrastructure.

Julie & Holleman LLP is investigating Personalis Inc.'s proposed acquisition by Tempus AI for $16.25 per share. The law firm is concerned about potential conflicts of interest given Tempus' existing significant equity stake and strategic relationship with Personalis since 2023, and whether shareholders are receiving fair value for their shares.

The iShares Semiconductor ETF (SOXX) is positioned to outperform the VanEck Semiconductor ETF (SMH) due to superior portfolio construction. While both are market-cap-weighted semiconductor ETFs with similar holdings, SOXX applies stricter weighting caps (8% for top 5 holdings, 4% for others) compared to SMH's 20% limit. This makes SMH dangerously concentrated with a 30% combined allocation to Nvidia and TSMC, creating significant concentration risk. SOXX's more diversified approach is expected to provide better risk-adjusted returns over the next 6-12 months.

Soitec reports on its liquidity contract managed by BNP Paribas for the first half of 2026. During H1 2026, 227,346 shares were purchased for €17.36 million and 288,875 shares were sold for €23.29 million across 4,546 transactions. The liquidity account held 24,442 shares and €6.36 million as of June 30, 2026.

SoFi Technologies has demonstrated exceptional customer growth, expanding from 5.2 million members in 2022 to 14.7 million by March 2026, representing 183% growth. The digital-only fintech company's competitive advantages include a superior user experience, innovative product pipeline, and high-yield savings accounts (3.1% APY), which have driven deposits to $40.2 billion. Management projects 30% annualized revenue growth from 2025-2028, supported by cross-selling opportunities and expanding customer base.

Investor rights law firm Halper Sadeh LLC is investigating Element Solutions Inc, Crinetics Pharmaceuticals Inc, and Solstice Advanced Materials Inc for potential securities law violations and breaches of fiduciary duties related to their proposed mergers and acquisitions. The firm is examining whether insiders are receiving preferential benefits and whether transaction terms may limit competing offers.